Related Experiment Videos
Diffuse well-differentiated lymphocytic lymphoma (DLWD): response and survival
Cancer
|October 1, 1978
Summary
Diffuse well-differentiated lymphocytic lymphoma (DLWD) shows poorer survival rates compared to nodular lymphocytic poorly differentiated lymphoma (NLPD). Aggressive chemotherapy is recommended for DLWD, as complete remission (CR) appears to improve survival outcomes.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Diffuse well-differentiated lymphocytic lymphoma (DLWD) is a subtype of non-Hodgkin lymphoma.
- Eastern Cooperative Oncology Group study (EST 1472) investigated treatment responses and survival outcomes.
Purpose of the Study:
- To analyze response rates and survival in patients with DLWD.
- To compare DLWD survival with nodular lymphocytic poorly differentiated lymphoma (NLPD).
Main Methods:
- Retrospective analysis of 34 DLWD patients from EST 1472.
- Evaluation of chemotherapy response rates (CR, PR, NC, PD).
- Survival analysis comparing DLWD with NLPD, considering lymphocytosis levels.
Main Results:
- DLWD response rates: CR 32%, PR 39%, NC/PD 29%.
- Two-year survivorship: CR 89%, PR 65%, NC 69%, PD 44%.
- DLWD showed significantly poorer two-year survival (67%) compared to NLPD (83%, p < .05).
Conclusions:
- DLWD is a less favorable lymphoma subtype than NLPD.
- Aggressive chemotherapy is indicated for DLWD.
- Achieving complete remission (CR) positively impacts DLWD patient survival.